Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Technology
Shanthi Rexaline

23andMe Pivoting To Clinical Research: Could That Lead To A Turnaround For The Stock?

Genetic testing company 23andMe Holding Co. (NASDAQ:ME) took the unconventional route of a SPAC deal to go public, and the stock hasn't gained much traction since it began trading on June 17, 2021.

The new year saw the company announcing its diversification into drug development. Will this pivot help a reversal in fortunes?

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.